Christalla P, Dewenter M, El-Armouche A
Abteilung Pharmakologie, Universitätsmedizin Göttingen.
Dtsch Med Wochenschr. 2012 May;137(18):940-4. doi: 10.1055/s-0032-1304895. Epub 2012 Apr 10.
Smoking is one of the major avoidable risks for mortality and morbidity. Thus developing new strategies for smoking cessation is a crucial medical challenge. Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist developed especially for smoking cessation. Several trials proved the efficacy of varenicline and its superiority to other medications for smoking cessation (bupropion and nicotine replacement therapy). Varenicline was associated with severe cardiovascular and neuro-psychiatric side effects. This article discusses the current research data on efficacy and safety of varenicline therapy for smoking cessation.
吸烟是导致死亡和发病的主要可避免风险之一。因此，开发新的戒烟策略是一项关键的医学挑战。伐尼克兰是一种专门为戒烟而开发的α4β2烟碱型乙酰胆碱受体部分激动剂。多项试验证明了伐尼克兰的疗效及其在戒烟方面优于其他药物（安非他酮和尼古丁替代疗法）。伐尼克兰与严重的心血管和神经精神副作用有关。本文讨论了伐尼克兰戒烟治疗疗效和安全性的当前研究数据。
